Literature DB >> 16888188

Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice.

Juan Luis Herrera1, Rafael Fernández-Montesinos, Elena González-Rey, Mario Delgado, David Pozo.   

Abstract

Studies focused on the development of diabetes in NOD mice-a model for human type 1 diabetes-have revealed that an autoimmune inflammatory process is produced by the effect of Th1 cells and their secreted cytokines. DNA vaccination has been shown to be an effective method for modulating immunity in viral infections and experimental autoimmune diseases, including diabetes. VIP's immunomodulatory properties are partly mediated by skewing the pattern of cytokines from a proinflammatory response to an anti-inflammatory response. Using gene delivery to express VIP, we interfered in the immune process leading to diabetes in prone, cyclophosphamide-treated NOD mice. Our results extend the role of VIP in the control of immunoregulatory networks and open new perspectives for immunointervention through VIP-based gene therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16888188     DOI： 10.1196/annals.1317.041

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  9 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.

Authors:  Fulya Erendor; Elif Ozgecan Sahin; Ahter D Sanlioglu; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Gene Ther       Date:  2020-07-30       Impact factor: 5.250

3.  Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.

Authors:  Miguel G Toscano; Mario Delgado; Weimin Kong; Francisco Martin; Mario Skarica; Doina Ganea
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

Review 4.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

Review 5.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

Authors:  Elena Gonzalez-Rey; Per Anderson; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

6.  Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes.

Authors:  Fulya Erendor; Yunus Emre Eksi; Elif Ozgecan Sahin; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

7.  Transcriptional modulation by VIP: a rational target against inflammatory disease.

Authors:  Hiba Ibrahim; Paul Barrow; Neil Foster
Journal:  Clin Epigenetics       Date:  2011-05-18       Impact factor: 6.551

8.  Single nucleotide polymorphisms in the 3'UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p.

Authors:  Fabiana Paladini; Nicla Porciello; Giorgio Camilli; Sinem Tuncer; Elisa Cocco; Maria Teresa Fiorillo; Rosa Sorrentino
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

Review 9.  Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.

Authors:  Per Anderson; Mario Delgado
Journal:  J Cell Mol Med       Date:  2008-06-28       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.